- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00223067
Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes
A Multi-Center Open-Labeled Study of the Administration of Allogenic and Autologous Regulatory Cells for the Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor)
Study Overview
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ulrich Kunzendorf
- Phone Number: 004315971338
- Email: kunzendorf@nephro.uni-kiel.de
Study Locations
-
-
-
Kiel, Germany, 24105
- Recruiting
- University of Schleswig-Holstein, Campus Kiel, Department of Nephrology
-
Contact:
- Ulrich Kunzendorf, MD
- Phone Number: 004315971338
- Email: Kunzendorf@nephro.uni-kiel.de
-
Sub-Investigator:
- Lutz Renders, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients must meet all the following inclusion criteria to be considered for admission to the trial:
Male or female adult patients aged between 18 and 64 years (inclusive). A female of childbearing potential may be enrolled provided she:
- has a negative pregnancy test at Screening and
- is routinely using adequate contraception prior to and during the study and
- agrees not to attempt to become pregnant during the study and
- is not lactating A female of non-childbearing potential will be defined as one who has been postmenopausal for at least one year or has been surgically sterilised.
- Patients receiving a first renal transplant.
- Patients who fulfil the criteria to receive an allogenic renal transplant (according to the Eurotransplant (ET) manual on organ allocation and the Bundesärztekammer allocation criteria) and who are listed on a waiting list.
- Patients who, after the nature of the study and the disclosure of their data has been explained to them, have freely given Informed Consent in writing.
- In vitro demonstration of the suppressive effect of the donor TAIC for the donor-recipient pair.
Exclusion Criteria (for the recipient)
Exclusion Criteria (for the recipient):
Patients presenting any of the following exclusion criteria must not be included in the trial:
- Patients who have received a renal transplant.
- Patients who have an active infection at the time of entry into the study (Screening).
- Recipient and donor pairs who show the following incompatible EBV or CMV constellation: the donor is EBV or CMV positive and the recipient is EBV or CMV negative.
- Patients and/or donors who have positive evidence of HIV or have active virus hepatitis B and C.
- Patients with a history of alcohol and/or drug abuse or sepsis.
- Patients who are pregnant women or nursing mothers.
- Known hypersensitivity or contraindication to one of the immunosuppressives administered during the course of the study: ATG, tacrolimus, or steroids (prednisolone).
- Patients with a history or present symptoms of autoimmune vasculitis.
- Detection of > 5% HLA antibodies (all current and historic values).
- Patients with a malignancy or history of malignancy.
- Patients with renal insufficiency due to a vasculitis.
- Patients whose condition requires continuous systemic administration of immunosuppressives.
- Missing immunosuppressive effect of the donor TAIC for the donor-recipient pair in vitro test.
- Patients who are simultaneously participating or plan to participate in any other clinical study.
- Psychiatric or emotional problems or lack of knowledge of the German language which would invalidate the giving of Informed Consent or limit the ability of the subject to comply with study requirements.
- Unwillingness or inability to provide Informed Consent or to participate satisfactorily for the entire trial period
- Patients with corresponding donors presenting any one of the exclusion criteria documented in the Eurotransplant guidelines ( ) must not be included in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
serum creatinine
|
rejection episodes
|
graft survival and reduction or withdrawal of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC) and autologous regulatory T cells (tregs)
|
necessity for re-introduction of any immunosuppressives.
|
Secondary Outcome Measures
Outcome Measure |
---|
safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) in terms of rejection episodes and Adverse Events (AEs)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ulrich Kunzendorf, MD, University of Schleswig-Holstein, Campus Kiel Department of Nephrology
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)Active, not recruitingKidney Transplantation | Renal Transplantation | Renal Transplant RecipientUnited States
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
NovartisCompletedOrgan Transplantation, Renal Transplantation
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedKidney Transplantation | Renal TransplantationUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
University of North Carolina, Chapel HillMallinckrodtWithdrawnKidney Transplantation | Renal Transplantation | FSGSUnited States
-
Bristol-Myers SquibbCompletedKidney Transplantation | Graft Rejection | Renal TransplantationUnited States
-
Rabin Medical CenterRecruitingRenal TransplantationIsrael
Clinical Trials on TAIZ
-
University Hospital Schleswig-HolsteinUnknown